Eledoisin
A peptide extracted from the posterior salivary glands of certain small octopi (Eledone spp., Mollusca), or obtained by synthesis. Its actions resemble those of SUBSTANCE P; it is a potent vasodilator and increases capillary permeability. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1364)
Networked: 24
relevant articles (1 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Ganglion Cysts (Ganglion)
06/30/1987
- " In these ganglia, both substance P and eledoisin are potent agonists, producing a slowly developing depolarization in ganglion neurons which is associated with an increase in input resistance and inhibition of the M-current. " 06/01/1963
- " Eledoisin is active at extremely low dose levels and hypotension is not appreciably affected by previous treatment with atropine, sympatholytic drugs, ganglion-blocking agents or reserpine. " 09/01/1969
- " During tachyphylaxis to eledoisin, nicotine and dimethylphenylpiperazinium were unable to restore peristalsis.3. When the peristaltic reflex had been abolished by ganglion-blocking agents, morphine and morphine-like substances, or adrenaline, eledoisin restored the reflex. " 09/01/1969
- " Eledoisin was much more effective in overcoming the blocking effect of hexamethonium, tetraethylammonium and azamethonium than that of nicotine or dimethylphenylpiperazinium.4. Eledoisin did not antagonize the inhibitory effects of atropine, hyoscine and hyoscine butylbromide.5. It is suggested that the stimulant effect of eledoisin may be due to a direct action on the smooth muscle and a release of acetylcholine from postganglionic nerve endings, but an effect on the intestinal ganglion cells cannot be excluded."
|
| 2. | Dry Eye Syndromes (Dry Eye Syndrome)
|
| 3. | Keratoconjunctivitis Sicca
02/01/1988
- " [Treatment of a severe course of keratoconjunctivitis sicca with eledoisin]." 01/01/1976
- " The clinical tests in 23 eyes of 14 patients with keratoconjunctivitis sicca proved satisfactory, since the lacrymal stimulating effect is not only greater, but lasts three times longer by combining the instillation of eledoisin with a presoaked soft lens. " 01/01/1975
- " [Use of a new drug, eledoisin, in the treatment of keratoconjunctivitis sicca]." 04/01/1988
- " [Eledoisin eyedrops in the therapy of keratoconjunctivitis sicca]." 01/01/1976
- " Another group of investigations was performed with two polypeptides with high molecular weight: Eledoisin, extracted from a mediterranean octopus, Eledone moschata, and Physalaemin, extracted from the skin of a south american batrachian, Physalaemus fuscomaculatus, both of these stimulate the lacrimal secretion and were previously successfully employed topically by the authors against keratoconjunctivitis sicca. "
|
| 4. | Carcinoid Tumor (Carcinoid)
11/01/1984
- " Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors." 06/01/1987
- " Reversed-phase high-performance liquid chromatography of the culture media with elevated tachykinin concentrations revealed immunoreactive components with the characteristics of synthetic neuropeptide K, neurokinin A and eledoisin, components also found in plasma and tumour tissues of carcinoid patients. " 08/01/1988
- " Flushing seen in fore-gut carcinoids (gastric carcinoids) has been ascribed to excessive histamine release, whereas flushing seen in mid-gut carcinoids (ileal carcinoids) tentatively has been ascribed to excessive release of serotonin, bradykinin, substance P, substance K or eledoisin. " 09/01/1986
- " In addition, the plasma concentration of tachykinin [TKLI(K12)], using an assay that detects NKA, NPK, kassinin, eledoisin, and NKB, but not substance P and physalaemin, and the urinary excretion of 5-hydroxyindole acetic acid (5-HIAA) were measured in 20 patients with midgut carcinoid tumors before and during treatment with human leucocyte interferon. "
|
| 5. | Tachycardia (Tachyarrhythmias)
|
|
Related Drugs and Biologics
Related Therapies and Procedures